TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00972478
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00972478
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00972478
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01448239
Drug: alirocumab SAR236553 (REGN727)
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Solution Route of administration: Subcutaneous
Study: NCT04647461
Drug: Brimonidine Tartrate 1.5mg
Normalized name: Timolol Maleate 5mg/1mL, Brimonidine Tartrate 1.5mg/1mL, Dorzolamide Hydrochloride 20mg/1mL Ophthalmic drops, solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop 3 times a day for 12 weeks to target eyes
Study: NCT02633761
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
Study: NCT02633761
Drug: Misoprostol 200mcg
Normalized name: MISOPROSTOL 200MCG TAB
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol 200mcg
Study: NCT00121797
Drug: antibiotics according to culture
Normalized name: casein, emmental cultured
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01538589
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prescribed by the physicians as a result of normal clinical practice
Study: NCT00208182
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03398278
Drug: Oxycodone Tamper Resistant
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally taking Oxycodone Tamper Resistant 40mg in fast state
Study: NCT02440100
Drug: PF-06648671
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
Study: NCT02440100
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
Study: NCT00814125
Drug: Anastrozole (Arimidex)
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg, orally, once daily
Study: NCT00814125
Drug: Tamoxifen (Nolvadex)
Normalized name: tamoxifen Oral Tablet [Nolvadex]
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg, orally, once daily
Study: NCT00054015
Drug: triapine
Normalized name: Triapine
DrugBank: Triapine (DB11940)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02127060
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: for 1 month postoperative period, vitamin C was administered orally to the patients.
Study: NCT05504057
Drug: Antihistamine
Normalized name: Antihistamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines
Study: NCT05504057
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine
Study: NCT04749615
Drug: Periarticular Injection (PAI)
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAI is a widely-utilized, surgeon-performed, analgesic intervention for TKA patients.
Study: NCT02530879
Drug: Omeprazole, Lansoprazole, Esomeprazole, Rantidine
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
Study: NCT03744806
Drug: Bevacizumab Injection
Normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01238211
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01238211
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01238211
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03679845
Drug: Sarilumab
Normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
Study: NCT04310007
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04310007
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04310007
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04310007
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04310007
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04174742
Drug: pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.
Study: NCT01708954
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01708954
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00050687
Drug: Gallium maltolate
Normalized name: Gallium maltolate
DrugBank: Gallium maltolate (DB05420)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00124397
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03292861
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 8 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4-8 hours.
Study: NCT03292861
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects
Study: NCT03292861
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter.
Study: NCT02252497
Drug: Active comparator : Tranexamic Acid (Exacyl)
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * 1g Exacyl Intra Venous, just before surgery~* Then infusion of 1g of Exacyl over eight hours .
Study: NCT03292861
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance doses of sirolimus at 12 months post-transplantation
Study: NCT04089163
Drug: Toca FC (extended-release formulation of flucytosine)
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
Study: NCT00294632
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting Dose 10 mg By Mouth Daily on Days 1-21
Study: NCT00294632
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 By Vein Weekly for 4 Weeks
Study: NCT01890785
Drug: Lisdexamfetamine Dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of a 70 mg capsule on Day 1
Study: NCT02715466
Drug: Balanced gelatine solution
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelaspan combined with Sterofundin ISO
Study: NCT04071626
Drug: Ertugliflozin 5 mg
Normalized name: ertugliflozin 5 MG
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin 5 mg once a day for 12 weeks
Study: NCT04580472
Drug: Cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.
Study: NCT01715415
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule (double-blind treatment period), tablet (open-label treatment period)
Study: NCT03736720
Drug: Liposomal Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01112683
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 \& 10 mg/d divided dose week three, 10mg/BID week four).
Study: NCT01754909
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
Study: NCT01866553
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg capsule BID oral use
Study: NCT01866553
Drug: Pegylated interferon α-2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25 - 40 microgram per week for subcutaneous use
Study: NCT00214500
Drug: migalastat HCl
Normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03170232
Drug: Danirixin 35 mg tablets
Normalized name: Danirixin
DrugBank: Danirixin (DB11922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
Study: NCT04495257
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter
Study: NCT04495257
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments
Study: NCT04495257
Drug: APX005M
Normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APX005M 0.3mg/kg intravenously (IV) every 3 weeks
Study: NCT01439347
Drug: Vincristine Sulfate Liposomes Injection (VSLI)
Normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.25 mg/m\^2 (without any dose cap) as an IV infusion over 60 minutes.
Study: NCT01439347
Drug: Vincristine Sulfate Injection (VSI)
Normalized name: vincristine sulfate Injection
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m\^2 with a 2 mg dose cap as an IV infusion over 10 minutes.
Study: NCT02284919
Drug: [18F]ISO-1
Normalized name: [18F]ISO-1
DrugBank: ISO-1 F-18 (DB14900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]ISO-1 PET/CT scan
Study: NCT02235909
Drug: Azilsartan Medoxomil Low-dose
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil low-dose (AZM-L) 10 mg
Study: NCT02235909
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02235909
Drug: Placebo for Azilsartan Medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02235909
Drug: Placebo for Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02235909
Drug: Azilsartan Medoxomil Medium-dose (20 mg)
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil medium-dose (AZM-M) 20 mg
Study: NCT02235909
Drug: Azilsartan Medoxomil High-dose (40 mg)
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil high-dose (AZM-L) 40 mg
Study: NCT02942355
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole by mouth daily
Study: NCT02942355
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib by mouth daily days 1-21 every 28 days
Study: NCT00882700
Drug: Cefdinir 300 mg Capsule (Sandoz, Austria)
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00882700
Drug: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03774173
Drug: Aramchol
Normalized name: Aramchol
DrugBank: Aramchol (DB11860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily
Study: NCT03724747
Drug: Darolutamide(BAY1841788)
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600 mg (2 X 300 mg tablets), twice daily with food, equivalent to a total daily dose of 1200 mg.
Study: NCT00883844
Drug: Nucleos(t)ide analogue treatment with a peginterferon add-on strategy
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
Study: NCT03724968
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be given by vein on day 1 of each cycle.
Study: NCT03724968
Drug: Relatlimab
Normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Relatlimab will be given by vein on day 1 of each 28-day cycle
Study: NCT03724968
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).
Study: NCT04575025
Drug: Tabrecta tablets
Normalized name: Tabrecta
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT01390506
Drug: Sodium-selenite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
Study: NCT01142466
Drug: Interferon beta-1a (Rebif)
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
Study: NCT00080288
Drug: Armodafinil 150 mg/day
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
Study: NCT02488902
Drug: Tafenoquine 25mg
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tafenoquine 25mg
Study: NCT02488902
Drug: Tafenoquine 50mg
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tafenoquine 50mg
Study: NCT02488902
Drug: Tafenoquine 100 mg
Normalized name: tafenoquine 100 MG
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tafenoquine 100 mg
Study: NCT02488902
Drug: Tafenoquine 200 mg
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tafenoquine 200 mg
Study: NCT02488902
Drug: Mefloquine 250 mg
Normalized name: mefloquine 250 mg oral tablet
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefloquine 250 mg
Study: NCT02979522
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin infusion
Study: NCT02979522
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinblastine infusion
Study: NCT02979522
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine infusion
Study: NCT01246973
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
Study: NCT03633019
Drug: rhTPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose rhTPO ih
Study: NCT01980316
Drug: Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
Study: NCT01980316
Drug: non-argatroban treated group
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in control group will receive Unfractionated heparin treatment
Study: NCT00525564
Drug: Salmeterol diskus inhalation powder
Normalized name: salmeterol Dry Powder Inhaler
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 micrograms twice a day
Study: NCT04268784
Drug: DNL343
Normalized name: DNL343
DrugBank: DNL343 (DB18678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and repeating oral dose(s)
Study: NCT00044005
Drug: Lurasidone 20 mg
Normalized name: lurasidone 20 mg oral tablet
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 20mg oral tablet taken once daily for 6-months
Study: NCT00044005
Drug: Lurasidone 40 mg
Normalized name: lurasidone 40 mg oral tablet
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 40mg oral tablets taken once daily
Study: NCT00044005
Drug: Lurasidone 80mg
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 80mg oral tablet taken once daily
Study: NCT02314273
Drug: rhIL-11
Normalized name: Oprelvekin (rhIL-11)
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
Study: NCT02100527
Drug: PF-05175157
Normalized name: PF-05175157
DrugBank: PF-05175157 (DB12096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
Study: NCT01664273
Drug: Plasmid AMEP
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts of 3 patients will received increasing doses of plasmid AMEP:~50 μg, 100 μg, 250 μg and 500 μg. Starting dose will be the lowest dose.~Injection volume will remain constant at 200 μL.~Once-only treatment and intra-individual dose escalation will therefore not occur.
Study: NCT03197571
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (SP-4-2)-diamminedichloroplatinum(II)
Study: NCT03197571
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
Study: NCT01837420
Drug: VB-201 80mg
Normalized name: VB-201
DrugBank: VB-201 (DB15259)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01837420
Drug: VB-201 160mg
Normalized name: VB-201
DrugBank: VB-201 (DB15259)
Approvals — FDA: no, EMA: no, PMDA: no